Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia.
about
Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemiaSelective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine.EBV-gp350 confers B-cell tropism to tailored exosomes and is a neo-antigen in normal and malignant B cells--a new option for the treatment of B-CLLMultifunctional CD40L: pro- and anti-neoplastic activity.In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo.T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma.Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia.Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia.Is cancer gene therapy an empty suit?Changing paradigms in the treatment of chronic lymphocytic leukemia.Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant.AdCD40L--crossing the valley of death?Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.Breaking immunotolerance of tumors: a new perspective for dendritic cell therapy.Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia.Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia.Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.Immunotherapy for B-cell lymphoma: current status and prospective advancesSelective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression.Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells.In vitro-activated tumor-bearing host T cells and the effectiveness of tumor vaccine immunotherapy.T cells stimulated by CD40L positive leukemic blasts-pulsed dendritic cells meet optimal functional requirements for adoptive T-cell therapy.New developments in immunotherapy for lymphoma
P2860
Q27001318-7CF19C77-4A62-418F-BB82-715676A69415Q33718767-4BABA467-A97B-498F-997D-51FDFB2C8C2AQ34055555-86517E2E-5BEA-4250-BB64-6EBAE92C4732Q34422566-64FE2CAE-4FC5-4B35-BA53-E7E11C11F27DQ35001579-081FC996-13AD-4042-87C6-F0B8310A9BF2Q35812085-0B13CCC9-A7FF-49E4-9FBE-C722AA4D8062Q35848840-B188E10A-F566-4D52-822B-5A7F594038BFQ36059585-F83B611F-B4FF-4C19-A267-8B66E3E25E6AQ36853440-A66518B4-69E5-44FE-8584-1677300E346EQ36941738-B3EC2ECC-BF6A-4F94-AC72-B58387A74081Q37268297-A6F1B088-2434-4AE6-8A8A-E68B106BDC2CQ37564361-08AD6091-605A-4B0B-9BB5-60EA5E6C25CCQ37662198-6CF63581-92A2-4C14-8D75-13846FF1DD72Q37773301-09EF38BD-03B1-423D-BD11-CE135FF84D49Q38026926-156281F8-90D3-4F62-8BBB-1669E4E20879Q38120535-194D1C38-82EA-47B8-B758-3E73722AC129Q38185156-F0BBD7D7-F85D-4453-9ABC-AA2512890924Q38259446-B6B33819-5EFA-4E3F-A506-C6C1128BEB92Q39718346-D0B61AFD-2722-407B-941F-3823634448A3Q39966752-44D0765D-74CA-42E2-9A4C-B16AD885B547Q41831989-0E331DE9-75FC-4564-88C8-B924422258ECQ42678254-D966D0DA-74B4-42D4-B116-17ED064EC1CCQ45862006-A01D4692-69A0-4A06-9CDD-0CB2C9B2230DQ50961597-E2A1005F-3B90-43C4-B030-C2077B2C0197Q51979179-AF03B469-F8F4-42E5-A953-82D387B0AAFAQ58804962-115E8330-1763-4CB2-982B-FB2AE36BDAA4
P2860
Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Responses to human CD40 ligand ...... chronic lymphocytic leukemia.
@en
type
label
Responses to human CD40 ligand ...... chronic lymphocytic leukemia.
@en
prefLabel
Responses to human CD40 ligand ...... chronic lymphocytic leukemia.
@en
P2093
P1476
Responses to human CD40 ligand ...... chronic lymphocytic leukemia.
@en
P2093
Aaron Foster
Adrian Gee
Bambi Grilley
Diana Havlik-Cooper
Ettore Biagi
George Carrum
Gianpietro Dotti
Kelty Baker
Lawrence Rice
P304
P356
10.1158/1078-0432.CCR-05-0484
P407
P433
P577
2005-10-01T00:00:00Z